Advertisement
Advertisement
BOLD
Boundless Bio, Inc. Common Stock
2.89
USDSponsored
+0.05
+1.76%
Aug 07, 15:59 UTC -4
Closed
After-Market
2.90
0.00
+0.17%
BOLD Earnings Reports
Positive Surprise Ratio
BOLD beat 4 of 9 last estimates.
44%
Next Report
Date of Next Report
Aug 17, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.59
Implied change from Q1 26 (Revenue/ EPS)
--
/-1.67%
Implied change from Q2 25 (Revenue/ EPS)
--
/-15.71%
Boundless Bio, Inc. Common Stock earnings per share and revenue
On May 08, 2026, BOLD reported earnings of -0.60 USD per share (EPS) for Q1 26, missing the estimate of -0.58 USD, resulting in a -2.01% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -5.88% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.59 USD, with revenue projected to reach -- USD, implying an decrease of -1.67% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were Boundless Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Boundless Bio, Inc. Common Stock reported EPS of -$0.60, missing estimates by -2.01%, and revenue of $0.00, 0% as expectations.
How did the market react to Boundless Bio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -5.88%, changed from $1.53 before the earnings release to $1.44 the day after.
When is Boundless Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 17, 2026.
What are the forecasts for Boundless Bio, Inc. Common Stock's next earnings report?
Based on 4
analysts, Boundless Bio, Inc. Common Stock is expected to report EPS of -$0.59 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement